Literature DB >> 17111894

Polymyalgia rheumatica and giant cell arteritis.

Brian Unwin1, Cynthia M Williams, William Gilliland.   

Abstract

Polymyalgia rheumatica and giant cell arteritis are common, closely related vasculitic conditions that almost exclusively occur in patients older than 50 years. They may be manifestations of the same underlying disease and often coexist. Patients with polymyalgia rheumatica usually present with acute onset of stiffness and pain in the shoulder and pelvic musculature, which may be accompanied by fever, malaise, and weight loss. If untreated, polymyalgia rheumatica may result in significant disability. Giant cell arteritis may manifest as visual loss or diplopia, abnormalities of the temporal artery such as tenderness or decreased pulsation, jaw claudication, and new-onset headaches. Erythrocyte sedimentation rate and temporal artery biopsy help make the diagnosis. Giant cell arteritis requires urgent diagnosis because without treatment it may lead to irreversible blindness. Patients with either condition also may have nonspecific symptoms. Corticosteroids are the mainstay of therapy for both conditions, with higher doses required for treatment of giant cell arteritis. Duration of corticosteroid therapy can be five years or longer before complete clinical remission is achieved. Monitoring for corticosteroid-associated side effects such as osteoporosis and diabetes, as well as for relapses and flare-ups, is key to chronic management. The prognosis for either condition, if treated, is good.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17111894

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  9 in total

Review 1.  The treatment of giant cell arteritis.

Authors:  J Alexander Fraser; Cornelia M Weyand; Nancy J Newman; Valérie Biousse
Journal:  Rev Neurol Dis       Date:  2008

2.  Comparable Rates of Glucocorticoid-Associated Adverse Events in Patients With Polymyalgia Rheumatica and Comorbidities in the General Population.

Authors:  Izzat Shbeeb; Divya Challah; Shafay Raheel; Cynthia S Crowson; Eric L Matteson
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-02-22       Impact factor: 4.794

3.  Positron emission tomography findings in a patient with multiple myeloma of polymyalgia rheumatica-like symptoms caused by paraneoplastic syndrome.

Authors:  Shingo Suzuki; Masatomi Ikusaka; Masahito Miyahara; Kiyoshi Shikino
Journal:  BMJ Case Rep       Date:  2014-04-09

Review 4.  Evidence-based Role of Aspirin in Giant Cell Arteritis: A Literature Review.

Authors:  Anum Qureshi; Fatima Halilu; Sam W Serafi; Howard Hauptman; Tristan Flack
Journal:  J Community Hosp Intern Med Perspect       Date:  2022-09-09

5.  Giant cell arteritis and mortality.

Authors:  R Wade Crow; Bradley J Katz; Judith E A Warner; Stephen C Alder; Kang Zhang; Susan Schulman; Kathleen B Digre
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-02-04       Impact factor: 6.053

6.  Stroke in the setting of giant cell arteritis: a case report.

Authors:  S McDermott; N Casey; D J Robinson; K M Tan
Journal:  Case Rep Med       Date:  2010-12-15

7.  Optimal management of giant cell arteritis and polymyalgia rheumatica.

Authors:  Rodger Charlton
Journal:  Ther Clin Risk Manag       Date:  2012-04-05       Impact factor: 2.423

Review 8.  [Rheumatological emergency on the edge of intensive care medicine].

Authors:  Peter Härle
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372

9.  Level of Adherence to Prophylactic Osteoporosis Medication amongst Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: A Cross-Sectional Study.

Authors:  A Emamifar; Rannveig Gildberg-Mortensen; S Andreas Just; N Lomborg; R Asmussen Andreasen; I M Jensen Hansen
Journal:  Int J Rheumatol       Date:  2015-09-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.